Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades.
We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications.
Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures.
Company Details
- Employees
- 24
- Address
- J.h. Oortweg 19, Leiden,south Holland 2333 Ch,netherlands
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.anavotx.com
- Keywords
- drug discovery, phospatase biology, oncology.
- HQ
- Leiden, South Holland
Anavo Therapeutics Bv Questions
Anavo Therapeutics Bv's website is http://www.anavotx.com
Anavo Therapeutics Bv's LinkedIn profile is https://nl.linkedin.com/company/anavo-therapeutics-bv
Anavo Therapeutics Bv has
24 employees.
View email and phone details for 24
employees at Anavo Therapeutics Bv.
Anavo Therapeutics Bv's industry is
Biotechnology Research
Anavo Therapeutics Bv's top competitors are
Reactosome,
Biolabs Heidelberg,
Tcelltech Gmbh,
Bimovis,
Biopro Baden-Württemberg Gmbh,
Biorn Life Science Cluster,
Phialogics - The Native Biologics Platform Company,
Heidelberg Epignostix Gmbh,
Panosome Gmbh,
Primmune Therapeutics.
Anavo Therapeutics Bv's categories are Biotechnology Research
